Clinical Trials Sponsored by Macera therapeutics

Total 6922 results

Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI

Gastroesophageal Reflux Disease (GERD)

United States
Ocera Therapeutics

Terminated

Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Pouchitis

United States
Marea Therapeutics

Recruiting

Study of MAR001 in Adults With Metabolic Dysfunction

Hypertriglyceridemia

Australia
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in the Treatment of Pouchitis

Pouchitis

United States
Ocera Therapeutics

Completed

AST-120 Used to Treat Mild Hepatic Encephalopathy (ASTUTE)

Mild Hepatic Encephalopathy

United States
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States, Belgium
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas

Intestinal Fistula | Inflammatory Bowel Disease

United States, Israel, Canada, United Kingdom, Germany, Belgium, Hungary, France, Austria, Czech Republic, Netherlands, Poland
Ocera Therapeutics

Completed

Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy (AST015)

Hepatic Encephalopathy

United States
Galera Therapeutics, Inc.

Terminated

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Unresectable Pancreatic Cancer | Borderline Resectable Pancreatic Cancer | SBRT

United States, France, United Kingdom, Canada
Galera Therapeutics, Inc.

Completed

A Phase 1 Study of the Safety and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) and GC4711 (IV Infusion) in Healthy Volunteers

Healthy Volunteers

Australia
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects

Healthy

United States
Galera Therapeutics, Inc.

Terminated

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC (GRECO-1)

NSCLC | SBRT | Non-metastatic

United States
Galera Therapeutics, Inc.

Completed

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Oral Mucositis

United States, Puerto Rico, Canada
Galera Therapeutics, Inc.

Completed

Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer

Head and Neck Cancer | Oral Mucositis

Spain, Switzerland, Belgium, Poland, Germany, Czechia
Galera Therapeutics, Inc.

Terminated

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

Covid19 | SARS-CoV-2 Infection

United States
Galera Therapeutics, Inc.

Completed

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

Radiation Induced Oral Mucositis

United States, Canada, Puerto Rico
Galera Therapeutics, Inc.

Completed

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx

United States
Galera Therapeutics, Inc.

Terminated

Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

Esophagitis

United States
Galera Therapeutics, Inc.

Completed

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Renal Impairment

United States
Tacere Therapeutics, Inc.

Terminated

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.

Hepatitis C

United States
Tacere Therapeutics, Inc.

Completed

Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C

Hepatitis C

United States
First People's Hospital of Hangzhou
Macera therapeutics

Not yet recruiting

Human HER2-targeted Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases

Gastric Cancer

China
Galera Therapeutics, Inc.
Celerion

Completed

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Healthy | Healthy Volunteers

United States
Ocera Therapeutics, Inc.

No longer available

Emergency Use of OCR-002 in Acute Liver Failure (ALF)

Acute Liver Failure

United States
Ocera Therapeutics, Inc.

Completed

OCR002-SP103 - Oral Immediate Release Study

Cirrhosis

United States
Ocera Therapeutics, Inc.

Completed

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) (STOP-HE)

Hepatic Encephalopathy | Acute Episode of Overt Hepatic Encephalopathy

Belgium, Germany, Italy, Spain, United States, France, Austria, Russian Federation, Czechia, Australia, Hungary, Israel, Netherlands, Bulgaria, Estonia, Denmark, New Zealand
University of Florida
Lacerta Therapeutics

Completed

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease (AAV9-GAA_IM)

Pompe Disease

United States
Galera Therapeutics, Inc.
Syneos Health

Completed

A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers

Healthy | Healthy Volunteers

Australia
Galera Therapeutics, Inc.
Syneos Health

Completed

A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

Healthy | Healthy Volunteers

Australia
Acer Therapeutics Inc.

Completed

Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause

Post-menopausal Vasomotor Symptoms

United States
ACEA Therapeutics, Inc.

Terminated

Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States, Spain, France
ACEA Therapeutics, Inc.

Completed

Study of AC0058TA in Healthy Male and Female Subjects

Healthy Volunteers

United States
Acer Therapeutics Inc.

Recruiting

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome (DiSCOVER)

Vascular Ehlers-Danlos Syndrome

United States
EKR Therapeutics, Inc
Pacira Pharmaceuticals, Inc

Completed

A Pharmacokinetic (PK) Study of Extended-Release Epidural Morphine in Upper Abdominal Surgery

Postoperative Pain
Texas A&M University
Ocera Therapeutics

Unknown

Metabolism of Ornithine Phenylacetate (OCERA OP)

Healthy

United States
Galera Therapeutics, Inc.
M.D. Anderson Cancer Center

Completed

Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer

Pancreatic Cancer | Stereotactic Body Radiation Therapy

United States
ACEA Therapeutics, Inc.
Hangzhou ACEA Pharmaceutical Research Co., Ltd.

Unknown

Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States
Acera Surgical, Inc.

Active, not recruiting

Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Diabetic Foot Ulcer | Venous Leg Ulcer

United States
Acera Surgical, Inc.

Completed

Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

Diabetic Foot Ulcer

United States
Acera Surgical, Inc.

Completed

Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers

Diabetic Foot Ulcer

United States
Acera Surgical, Inc.

Terminated

Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site

Wound Heal

United States
Galera Therapeutics, Inc.
INC Research Australia Pty Ltd; Nucleous Network

Completed

A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers

Healthy Volunteer

Australia
Acerta Pharma BV
Acerta Pharma, LLC

Completed

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma (MM)

United States, United Kingdom
Natera, Inc.

Recruiting

Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Management. (ZTWINS)

Pregnancy Complications | Twin to Twin Transfusion Syndrome | Multiple Gestation; Maternal Care

United States
Natera, Inc.

Active, not recruiting

LAMBDA 002 (Lung Registry) Study

Lung Transplant Rejection

United States
Natera, Inc.

Active, not recruiting

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study (RenaCARE)

Kidney Diseases

United States
Kancera AB

Completed

Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567

Healthy

Finland
Lycera Corp.

Terminated

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

Colitis, Ulcerative

United States, Czechia, Hungary, Netherlands, Poland, Serbia
Natera, Inc.

Withdrawn

Multi-disease Carrier Screening Test Validation

Genetic Testing | Spinal Muscular Atrophy (SMA) | Carrier Screening

United States

3

Subscribe